ATE222921T1 - Modifizierte oligonukleotide - Google Patents

Modifizierte oligonukleotide

Info

Publication number
ATE222921T1
ATE222921T1 AT95906958T AT95906958T ATE222921T1 AT E222921 T1 ATE222921 T1 AT E222921T1 AT 95906958 T AT95906958 T AT 95906958T AT 95906958 T AT95906958 T AT 95906958T AT E222921 T1 ATE222921 T1 AT E222921T1
Authority
AT
Austria
Prior art keywords
pct
nucleotides
sec
modified oligonucleotides
date
Prior art date
Application number
AT95906958T
Other languages
English (en)
Inventor
Mesmaeker Alain De
Adrian Waldner
Jacques Lebreton
Marc-Olivier Bevierre
Catherine Lesueur
Original Assignee
Novartis Erfind Verwalt Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9401446A external-priority patent/GB9401446D0/en
Priority claimed from GB9412526A external-priority patent/GB9412526D0/en
Application filed by Novartis Erfind Verwalt Gmbh filed Critical Novartis Erfind Verwalt Gmbh
Application granted granted Critical
Publication of ATE222921T1 publication Critical patent/ATE222921T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT95906958T 1994-01-26 1995-01-17 Modifizierte oligonukleotide ATE222921T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9401446A GB9401446D0 (en) 1994-01-26 1994-01-26 Modified oligonucleotides
GB9412526A GB9412526D0 (en) 1994-06-22 1994-06-22 Modified oligonucleotides
PCT/EP1995/000156 WO1995020597A1 (en) 1994-01-26 1995-01-17 Modified oligonucleotides

Publications (1)

Publication Number Publication Date
ATE222921T1 true ATE222921T1 (de) 2002-09-15

Family

ID=26304218

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95906958T ATE222921T1 (de) 1994-01-26 1995-01-17 Modifizierte oligonukleotide

Country Status (13)

Country Link
US (1) US6066447A (de)
EP (1) EP0741741B1 (de)
JP (1) JPH09508134A (de)
AT (1) ATE222921T1 (de)
AU (1) AU697134B2 (de)
CA (1) CA2180727A1 (de)
DE (1) DE69527942T2 (de)
DK (1) DK0741741T3 (de)
FI (1) FI116677B (de)
HU (1) HU220423B (de)
IL (1) IL112424A0 (de)
NO (1) NO316902B1 (de)
WO (1) WO1995020597A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0734433B2 (de) * 1993-12-13 2004-03-24 The Procter & Gamble Company Viskositätsstabile konzentrierte weichspülerzusammensetzungen
US6166197A (en) * 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US6222025B1 (en) 1995-03-06 2001-04-24 Isis Pharmaceuticals, Inc. Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom
WO1997014709A1 (en) * 1995-10-13 1997-04-24 F. Hoffmann-La Roche Ag Antisense oligomers
US5808035A (en) * 1995-12-08 1998-09-15 Usher; David A. Protected nucleoside and method for its synthesis
AU3340797A (en) * 1996-06-28 1998-01-21 Novartis Ag Modified oligonucleotides
HRP980375A2 (en) 1997-07-03 1999-04-30 Argyrios Georgios Arvanitis Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
AP1411A (en) 1998-06-02 2005-05-10 Osi Pharm Inc Pyrrolo[2,3d] pyrimidine compositions and their use.
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
JP2005529062A (ja) 2001-11-30 2005-09-29 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アデノシンａ１及びａ３受容体に特異的な化合物とその使用
CN101973998A (zh) 2001-12-20 2011-02-16 Osi药物公司 吡咯并嘧啶A2b选择性拮抗剂化合物
JP4440642B2 (ja) 2001-12-20 2010-03-24 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ピリミジンＡ２ｂ選択的アンタゴニスト化合物、それらの合成、及び使用
KR100649352B1 (ko) * 2005-04-30 2006-11-27 주식회사 하이닉스반도체 반도체소자의 제조 방법
US7820810B2 (en) 2007-03-19 2010-10-26 Isis Pharmaceuticals, Inc. Process for the synthesis of 2′-O-substituted purine nulceosides
MX2011010050A (es) 2009-03-25 2011-12-14 Univ Texas Composiciones para estimulación de resistencia inmune innata de mamiferos a patógenos.
US10286065B2 (en) 2014-09-19 2019-05-14 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
MX2018001315A (es) * 2015-07-30 2018-08-15 Horizon Orphan Llc Inhibidores de fucosidasa.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
EP0266099A3 (de) * 1986-10-28 1990-09-19 The Johns Hopkins University Alkyl- oder Arylphosphonat-Oligonukleosid, das sich mit Nukleinesäuren vernetzen kann oder das Nukleinsäure spalten kann
EP0402402B1 (de) * 1988-02-26 1995-12-27 Worcester Foundation For Biomedical Research, Inc. Hemmung von htlv-iii durch exogene oligonukleotide
EP0942000B1 (de) * 1989-10-24 2004-06-23 Isis Pharmaceuticals, Inc. 2'-Modifizierte Oligonukleotide
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
WO1992002534A2 (en) * 1990-08-03 1992-02-20 Sterling Drug, Inc. Compounds and methods for inhibiting gene expression
WO1992005186A1 (en) * 1990-09-20 1992-04-02 Gilead Sciences Modified internucleoside linkages

Also Published As

Publication number Publication date
HU9602040D0 (en) 1996-09-30
AU697134B2 (en) 1998-09-24
AU1534795A (en) 1995-08-15
JPH09508134A (ja) 1997-08-19
EP0741741B1 (de) 2002-08-28
EP0741741A1 (de) 1996-11-13
NO963092L (no) 1996-09-16
FI116677B (fi) 2006-01-31
DK0741741T3 (da) 2002-12-23
HUT75704A (en) 1997-05-28
NO316902B1 (no) 2004-06-21
HU220423B (hu) 2002-01-28
DE69527942T2 (de) 2003-03-27
DE69527942D1 (de) 2002-10-02
FI962980A0 (fi) 1996-07-26
FI962980A (fi) 1996-07-26
NO963092D0 (no) 1996-07-24
IL112424A0 (en) 1995-03-30
CA2180727A1 (en) 1995-08-03
WO1995020597A1 (en) 1995-08-03
US6066447A (en) 2000-05-23

Similar Documents

Publication Publication Date Title
ATE222921T1 (de) Modifizierte oligonukleotide
MX9703192A (es) Nucleosidos modificados en el azucar y su uso para la sintesis de oligonucleosidos.
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
DK0712860T3 (da) Fremgangsmåde til oprensning og isolation af 2'-deoxy-2',2'-diflournukleosider
ATE373671T1 (de) Aminooxy-modifizierte oligonukleotide
DE3854297D1 (de) Nucleoside und nucleotide mit antiviraler, antitumoraler, antimetastatischer sowie immunstimulierender wirkung.
ES2061416T1 (es) Ribocimas modificadas.
CA2002648A1 (en) 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives
NZ332834A (en) Glycosaminoglycan-related carbohydrate derivatives ( 5 saccharide groups ) having 4 to 6 sulphate groups
ATE53588T1 (de) Herstellung von cytosin-nukleosiden.
DK630589A (da) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor-sammensaetning
BR9801143A (pt) Copolìmeros de bloco de siloxano inovativos com espaçamento rìgidos e uso dos mesmos.
FI960486A (fi) Loislääkkeitä
DE69323191T2 (de) Wasserlösliche retinoide
ES2090995T3 (es) Copolimeros de siloxano que contienen grupos viniloxi, su preparacion y utilizacion.
AU2739797A (en) (in situ) preparation of nucleoside phosphoramidites and their use in synthesis of oligonucleotides
NO962848D0 (no) Monohydrat av (E)-2'-deoksy-2'-(fluormetylen)cytidin
DK0611373T3 (da) Oligo-2-desoxynukleotider og deres anvendelse som lægemidler med antiviral virkning.
DE69407180T2 (de) Fluoro-nukleosid-reinigung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties